1
|
Suryanto ME, Audira G, Uapipatanakul B, Hussain A, Saputra F, Siregar P, Chen KHC, Hsiao CD. Antidepressant Screening Demonstrated Non-Monotonic Responses to Amitriptyline, Amoxapine and Sertraline in Locomotor Activity Assay in Larval Zebrafish. Cells 2021; 10:cells10040738. [PMID: 33810553 PMCID: PMC8066259 DOI: 10.3390/cells10040738] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/27/2021] [Revised: 03/19/2021] [Accepted: 03/23/2021] [Indexed: 12/15/2022] Open
Abstract
Antidepressants are well-known drugs to treat depression and major depressive disorder for humans. However, the misuse and abuse of antidepressants keep increasing with several side effects reported. The aim of this study was to assess the potential adverse effects of 18 antidepressants by monitoring zebrafish larval locomotor activity performance based on the total distance traveled, burst movement count, and total rotation count at four dark-light intercalated phases. In general, zebrafish larvae displayed sedative effects after antidepressant exposure by showing a significant reduction in all of the locomotor activity-related endpoints. However, three antidepressants i.e., amitriptyline, amoxapine, and sertraline were able to trigger a significantly high locomotor activity in zebrafish larvae during the light cycle. These differences might be due to the pharmacologic differences among the antidepressants. In addition, since each antidepressant possesses a different dosage range from the other, overdoses of these antidepressants might also be the causes of these differences. Furthermore, based on these results, a further study was conducted to observe the effect of these three antidepressants in lower concentrations. From the results, biphasic effects in terms of zebrafish larval locomotor activity were demonstrated by these drugs. Even though further studies are still required to validate the mechanism, these findings indicate that these antidepressants might share a common mechanism responsible for their effects on zebrafish larval locomotor activity although there were some differences in potency of these effects.
Collapse
Affiliation(s)
- Michael Edbert Suryanto
- Department of Bioscience Technology, Chung Yuan Christian University, Chung-Li 320314, Taiwan; (M.E.S.); (G.A.); (A.H.); (F.S.); (P.S.)
| | - Gilbert Audira
- Department of Bioscience Technology, Chung Yuan Christian University, Chung-Li 320314, Taiwan; (M.E.S.); (G.A.); (A.H.); (F.S.); (P.S.)
- Department of Chemistry, Chung Yuan Christian University, Chung-Li 320314, Taiwan
| | - Boontida Uapipatanakul
- Department of Chemistry, Faculty of Science and Technology, Rajamangala University of Technology Thanyaburi, Thanyaburi 12110, Thailand;
| | - Akhlaq Hussain
- Department of Bioscience Technology, Chung Yuan Christian University, Chung-Li 320314, Taiwan; (M.E.S.); (G.A.); (A.H.); (F.S.); (P.S.)
| | - Ferry Saputra
- Department of Bioscience Technology, Chung Yuan Christian University, Chung-Li 320314, Taiwan; (M.E.S.); (G.A.); (A.H.); (F.S.); (P.S.)
| | - Petrus Siregar
- Department of Bioscience Technology, Chung Yuan Christian University, Chung-Li 320314, Taiwan; (M.E.S.); (G.A.); (A.H.); (F.S.); (P.S.)
| | - Kelvin H.-C. Chen
- Department of Applied Chemistry, National Pingtung University, Pingtung 900391, Taiwan
- Correspondence: (K.H.-C.C.); (C.-D.H.)
| | - Chung-Der Hsiao
- Department of Bioscience Technology, Chung Yuan Christian University, Chung-Li 320314, Taiwan; (M.E.S.); (G.A.); (A.H.); (F.S.); (P.S.)
- Department of Chemistry, Chung Yuan Christian University, Chung-Li 320314, Taiwan
- Center for Nanotechnology, Chung Yuan Christian University, Chung-Li 320314, Taiwan
- Correspondence: (K.H.-C.C.); (C.-D.H.)
| |
Collapse
|
2
|
Association of Sleep Architecture and Physiology with Depressive Disorder and Antidepressants Treatment. Int J Mol Sci 2021; 22:ijms22031333. [PMID: 33572767 PMCID: PMC7866255 DOI: 10.3390/ijms22031333] [Citation(s) in RCA: 24] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2021] [Revised: 01/25/2021] [Accepted: 01/27/2021] [Indexed: 01/27/2023] Open
Abstract
Sleep problems are frequently associated with the principal diagnostic criteria for many mental disorders. Alterations in the sleep of depressive patients are of high clinical significance because continuous sleep problems raise the chance of relapse, recurrence, or suicide, as well as the need for augmenting medications. Most antidepressants have been proven to influence the sleep architecture. While some classes of antidepressants improve sleep, others may cause sleep impairment. The successful treatment of depressive disorder also requires an understanding of the effects of antidepressants on sleep. This article briefly reviews the physiology of sleep and the typical alterations in the sleep architecture in depressive patients and updates the different effects of the majority of antidepressants including novel drugs in clinical practice on sleep. The summary of the updated scientific findings of the relationship between depression and sleep disturbances could be clinically beneficial in choosing the best medication for depressive patients with concurrent sleep disorders.
Collapse
|
3
|
Abstract
Over the past decade, basic sleep research investigating the circuitry controlling sleep and wakefulness has been boosted by pharmacosynthetic approaches, including chemogenetic techniques using designed receptors exclusively activated by designer drugs (DREADD). DREADD offers a series of tools that selectively control neuronal activity as a way to probe causal relationship between neuronal sub-populations and the regulation of the sleep-wake cycle. Following the path opened by optogenetics, DREADD tools applied to discrete neuronal sub-populations in numerous brain areas quickly made their contribution to the discovery and the expansion of our understanding of critical brain structures involved in a wide variety of behaviors and in the control of vigilance state architecture.
Collapse
|
4
|
Chazalon M, Dumas S, Bernard JF, Sahly I, Tronche F, de Kerchove d'Exaerde A, Hamon M, Adrien J, Fabre V, Bonnavion P. The GABAergic Gudden's dorsal tegmental nucleus: A new relay for serotonergic regulation of sleep-wake behavior in the mouse. Neuropharmacology 2018; 138:315-330. [PMID: 29908240 DOI: 10.1016/j.neuropharm.2018.06.014] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/22/2017] [Revised: 05/28/2018] [Accepted: 06/10/2018] [Indexed: 11/17/2022]
Abstract
Serotonin (5-HT) neurons are involved in wake promotion and exert a strong inhibitory influence on rapid eye movement (REM) sleep. Such effects have been ascribed, at least in part to the action of 5-HT at post-synaptic 5-HT1A receptors (5-HT1AR) in the brainstem, a major wake/REM sleep regulatory center. However, the neuroanatomical substrate through which 5-HT1AR influence sleep remains elusive. We therefore investigated whether a brainstem structure containing a high density of 5-HT1AR mRNA, the GABAergic Gudden's dorsal tegmental nucleus (DTg), may contribute to 5-HT-mediated regulatory mechanisms of sleep-wake stages. We first found that bilateral lesions of the DTg promote wake at the expense of sleep. In addition, using local microinjections into the DTg in freely moving mice, we showed that local activation of 5-HT1AR by the prototypical agonist 8-OH-DPAT enhances wake and reduces deeply REM sleep duration. The specific involvement of 5-HT1AR in the latter effects was further demonstrated by ex vivo extracellular recordings showing that the selective 5-HT1AR antagonist WAY 100635 prevented DTg neuron inhibition by 8-OH-DPAT. We next found that GABAergic neurons of the ventral DTg exclusively targets glutamatergic neurons of the lateral mammillary nucleus (LM) in the posterior hypothalamus by means of anterograde and retrograde tracing techniques using cre driver mouse lines and a modified rabies virus. Altogether, our findings strongly support the idea that 5-HT-driven enhancement of wake results from 5-HT1AR-mediated inhibition of DTg GABAergic neurons that would in turn disinhibit glutamatergic neurons in the mammillary bodies. We therefore propose a Raphe→DTg→LM pathway as a novel regulatory circuit underlying 5-HT modulation of arousal.
Collapse
Affiliation(s)
- Marine Chazalon
- Laboratory of Neurophysiology, Université Libre de Bruxelles (ULB), ULB Neurosciences Institute, Brussels, Belgium
| | | | - Jean-François Bernard
- Sorbonne Paris Cité, Université Paris Descartes, Inserm, Centre de Psychiatrie et Neurosciences (CPN), 75014, Paris, France; Sorbonne Universités, UPMC Univ Paris 06, Inserm, CNRS, Neuroscience Paris Seine (NPS), Institut de Biologie Paris Seine (IBPS), 75005, Paris, France
| | - Iman Sahly
- Sorbonne Universités, UPMC Univ Paris 06, Inserm, CNRS, Neuroscience Paris Seine (NPS), Institut de Biologie Paris Seine (IBPS), 75005, Paris, France
| | - François Tronche
- Sorbonne Universités, UPMC Univ Paris 06, Inserm, CNRS, Neuroscience Paris Seine (NPS), Institut de Biologie Paris Seine (IBPS), 75005, Paris, France
| | - Alban de Kerchove d'Exaerde
- Laboratory of Neurophysiology, Université Libre de Bruxelles (ULB), ULB Neurosciences Institute, Brussels, Belgium
| | - Michel Hamon
- Sorbonne Paris Cité, Université Paris Descartes, Inserm, Centre de Psychiatrie et Neurosciences (CPN), 75014, Paris, France; Sorbonne Universités, UPMC Univ Paris 06, Inserm, CNRS, Neuroscience Paris Seine (NPS), Institut de Biologie Paris Seine (IBPS), 75005, Paris, France
| | - Joëlle Adrien
- Université Paris Descartes, VIFASOM, Hôtel-Dieu de Paris, 75004, Paris, France
| | - Véronique Fabre
- Sorbonne Universités, UPMC Univ Paris 06, Inserm, CNRS, Neuroscience Paris Seine (NPS), Institut de Biologie Paris Seine (IBPS), 75005, Paris, France.
| | - Patricia Bonnavion
- Laboratory of Neurophysiology, Université Libre de Bruxelles (ULB), ULB Neurosciences Institute, Brussels, Belgium; Sorbonne Paris Cité, Université Paris Descartes, Inserm, Centre de Psychiatrie et Neurosciences (CPN), 75014, Paris, France.
| |
Collapse
|
5
|
Simon PYR, Rousseau PF. Treatment of Post-Traumatic Stress Disorders with the Alpha-1 Adrenergic Antagonist Prazosin. CANADIAN JOURNAL OF PSYCHIATRY. REVUE CANADIENNE DE PSYCHIATRIE 2017; 62:186-198. [PMID: 27432823 PMCID: PMC5317016 DOI: 10.1177/0706743716659275] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
OBJECTIVE The present review aims to assess the clinical efficacy and safety of the α-1-adrenergic antagonist prazosin as primary pharmacologic treatment for post-traumatic stress disorder (PTSD). METHOD A systematic review was performed using keywords (i.e., prazosin, α-1-adrenergic antagonist, α-1-blocker, post-traumatic stress disorder) in the databases PubMed/Medline (1966-May 2016), Embase (1966-May 2016), ScienceDirect (1823-May 2016), OvidSP (1946-May 2016) and Nature (1845-May 2016). To be considered for inclusion, studies had to test the efficacy of prazosin either alone or added to ongoing treatment in adults with PTSD, use validated tools to assess and monitor the disorders, allow comparisons on the basis of univariate analyses (i.e., p-values of t-tests and effect sizes) and list the identified adverse reactions. RESULTS 12 studies were included: 5 randomized controlled trials, 4 open-label prospective trials and 3 retrospective file reviews. The evaluation concerned 276 patients exposed to civilian trauma (19%) or war trauma (81%). Prazosin significantly decreases trauma nightmares, avoidance, hypervigilance and improves patient status in all studies. No significant difference of blood pressure was observed at the end of trials. CONCLUSIONS Beyond the methodological and clinical biases of these studies, the present review not only confirms the effectiveness and good tolerability of prazosin, but also suggests its possible use as primary pharmacologic treatment for PTSD. Uncertainties remain, however, regarding the prescription modalities and dosages.
Collapse
Affiliation(s)
- Philippe Yves Rémy Simon
- Recherche clinique, Hôpital d’Instruction des Armées Sainte-Anne, Toulon, France
- Philippe Yves Rémy Simon, PhD, HIA Sainte-Anne, Recherche clinique, BP 20545, 83041 Toulon cedex 9, France. Courriel:
| | | |
Collapse
|
6
|
Vas S, Kátai Z, Kostyalik D, Pap D, Molnár E, Petschner P, Kalmár L, Bagdy G. Differential adaptation of REM sleep latency, intermediate stage and theta power effects of escitalopram after chronic treatment. J Neural Transm (Vienna) 2012; 120:169-76. [DOI: 10.1007/s00702-012-0847-2] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/15/2012] [Accepted: 06/08/2012] [Indexed: 10/28/2022]
|
7
|
Abstract
Many neurochemical systems interact to generate wakefulness and sleep. Wakefulness is promoted by neurons in the pons, midbrain, and posterior hypothalamus that produce acetylcholine, norepinephrine, dopamine, serotonin, histamine, and orexin/hypocretin. Most of these ascending arousal systems diffusely activate the cortex and other forebrain targets. NREM sleep is mainly driven by neurons in the preoptic area that inhibit the ascending arousal systems, while REM sleep is regulated primarily by neurons in the pons, with additional influence arising in the hypothalamus. Mutual inhibition between these wake- and sleep-regulating regions likely helps generate full wakefulness and sleep with rapid transitions between states. This up-to-date review of these systems should allow clinicians and researchers to better understand the effects of drugs, lesions, and neurologic disease on sleep and wakefulness.
Collapse
Affiliation(s)
- Rodrigo A España
- Department of Physiology and Pharmacology, Wake Forest University Health Sciences, Winston Salem, NC, USA
| | | |
Collapse
|
8
|
Vázquez-Palacios G, Hernández-González M, Guevara Pérez MÁ, Bonilla-Jaime H. Nicotine and fluoxetine induce arousing effects on sleep–wake cycle in antidepressive doses: A possible mechanism of antidepressant-like effects of nicotine. Pharmacol Biochem Behav 2010; 94:503-9. [DOI: 10.1016/j.pbb.2009.11.004] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/09/2009] [Revised: 10/30/2009] [Accepted: 11/11/2009] [Indexed: 01/09/2023]
|
9
|
Real C, Seif I, Adrien J, Escourrou P. Ondansetron and fluoxetine reduce sleep apnea in mice lacking monoamine oxidase A. Respir Physiol Neurobiol 2009; 168:230-8. [PMID: 19615472 DOI: 10.1016/j.resp.2009.07.003] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/12/2008] [Revised: 06/07/2009] [Accepted: 07/07/2009] [Indexed: 10/20/2022]
Abstract
Prospective clinical trials addressing the role of serotonin (5-HT) in sleep apnea have indicated that the 5-HT uptake inhibitor fluoxetine is beneficial to some patients with obstructive apnea, whereas the 5-HT(3) receptor antagonist ondansetron seems of little value despite its efficacy in rat and dog models of sleep apnea (central and obstructive). Here, we examined the effect of these drugs in transgenic mice lacking monoamine oxidase A (Tg8), which exhibit approximately 3-fold higher rates of central sleep apnea than their wild-type counterparts (C3H), linked to their enhanced 5-HT levels. Acute ondansetron (2 mg kg(-1), intraperitoneal), acute fluoxetine (16 mg kg(-1)) and 13-day chronic fluoxetine (1 or 16 mg kg(-1)) decreased by approximately 80% the total (spontaneous and post-sigh) apnea index in Tg8 mice during non-rapid eye movement sleep, with no statistically significant effect on apnea in C3H mice. Our study shows that both drugs reduce the frequency of apneic episodes attributable to increased monoamine levels in this model of MAOA deficiency, and suggests that both may be effective in some patients with central sleep apneas.
Collapse
Affiliation(s)
- C Real
- Univ Paris-Sud, EA 3544, Sérotonine et Neuropharmacologie, Châtenay-Malabry cedex, France.
| | | | | | | |
Collapse
|
10
|
Ayala-Guerrero F, Mexicano G, González V, Hernandez M. Effect of oxcarbazepine on sleep architecture. Epilepsy Behav 2009; 15:287-90. [PMID: 19379835 DOI: 10.1016/j.yebeh.2009.04.013] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/16/2008] [Revised: 04/07/2009] [Accepted: 04/13/2009] [Indexed: 11/19/2022]
Abstract
The most common side effects following administration of antiepileptic drugs involve alterations in sleep architecture and varying degrees of daytime sleepiness. Oxcarbazepine is a drug that is approved as monotherapy for the treatment of partial seizures and generalized tonic-clonic seizures. However, there is no information about its effects on sleep pattern organization; therefore, the objective of this work was to analyze such effects. Animals (Wistar rats) exhibited three different behavioral and electrophysiological states of vigilance: wakefulness, slow wave sleep (SWS), and rapid eye movement (REM) sleep. Oral treatment with oxcarbazepine (100 mg/kg) produced an increment in total sleep time throughout the recording period. This increment involved both SWS and REM sleep. Mean duration of the REM sleep phase was not affected. In contrast, the frequency of this sleep phase increased significantly across the 10-hour period. REM sleep latency shortened significantly. Results obtained in this work indicate that oxcarbazepine's acute effects point to hypnotic properties.
Collapse
Affiliation(s)
- Fructuoso Ayala-Guerrero
- Facultad de Psicología, Universidad Nacional Autónoma de México, Avenida Universidad 3004, Col. Copilco-Universidad, 04510 Del. Coyoacán, Mexico.
| | | | | | | |
Collapse
|
11
|
Cespuglio R, Rousset C, Debilly G, Rochat C, Millan MJ. Acute administration of the novel serotonin and noradrenaline reuptake inhibitor, S33005, markedly modifies sleep-wake cycle architecture in the rat. Psychopharmacology (Berl) 2005; 181:639-52. [PMID: 15983796 DOI: 10.1007/s00213-005-0016-5] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/04/2004] [Accepted: 03/29/2005] [Indexed: 11/26/2022]
Abstract
RATIONALE The interrelationship between depressive states and sleep-wake cycle architecture is characterised by a decreased latency to the first paradoxical sleep (PS) episode, together with an enhancement of PS during the first part of the night. Conversely, slow-wave sleep (SWS) is decreased and intermittent awakenings increased. Notably, antidepressant treatment is generally associated with a diminution of PS. OBJECTIVES In light of these observations, we examined the influence of acute administration of the novel mixed serotonin-noradrenaline reuptake blocker, (-)1-(1-dimethylaminomethyl 5-methoxybenzocyclobutan-1-yl)-cyclohexanol HCl (S33005), upon sleep-wake architecture in rats. METHODS Animals were injected with vehicle or incremental doses of S33005 at the onset of either the dark or light periods. Digitised polygraphic recordings were performed, and changes evoked by S33005 were determined over 24-h recording periods, i.e., number and duration of sleep-wake episodes, latencies to PS and SWS, power band spectra of the electroencephalogram (EEG) and circadian changes. RESULTS At 0.04 mg/kg, S33005 was inactive, whereas at 0.63 mg/kg, it modestly increased PS latencies and diminished PS duration during the light period. At 10 mg/kg, S33005 reduced markedly PS duration for about 4-h when injected prior to both light and dark periods. Latency to PS was prolonged, and the circadian acrophase was delayed. These effects are in keeping with previous studies of monoamine reuptake inhibitors, but, notably, SWS duration was increased when S33005 was injected at the onset of the light phase (+4%). These changes occurred without marked modifications in circadian rhythmicity or EEG spectral band power. Finally, even at the highest dose of S33005, only a limited rebound of SWS (+5%) and PS (+10%) was apparent. Amongst antidepressant to date examined, this is an original profile of influence upon sleep patterns. CONCLUSIONS These results demonstrate a pattern of influence of S33005 upon sleep-wake architecture in rats which is globally consistent with antidepressant properties, but with a distinctive enhancement of restorative slow-wave sleep.
Collapse
Affiliation(s)
- Raymond Cespuglio
- EA 3734 & IFR19, C. Bernard Univ., 8 av. Rockefeller, 69373, Lyon Cedex 08, France.
| | | | | | | | | |
Collapse
|
12
|
Monaca C, Boutrel B, Hen R, Hamon M, Adrien J. 5-HT 1A/1B receptor-mediated effects of the selective serotonin reuptake inhibitor, citalopram, on sleep: studies in 5-HT 1A and 5-HT 1B knockout mice. Neuropsychopharmacology 2003; 28:850-6. [PMID: 12637954 DOI: 10.1038/sj.npp.1300109] [Citation(s) in RCA: 64] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Selective serotonin reuptake inhibitors (SSRIs) are extensively used for the treatment of depression. Aside from their antidepressant properties, they provoke a deficit in paradoxical sleep (PS) that is most probably mediated by the transporter blockade-induced increase in serotonin concentration in the extracellular space. Such an effect can be accounted for by the action of serotonin at various types of serotonergic receptors involved in PS regulation, among which the 5-HT(1A) and 5-HT(1B) types are the best candidates. According to this hypothesis, we examined the effects of citalopram, the most selective SSRI available to date, on sleep in the mouse after inactivation of 5-HT(1A) or 5-HT(1B) receptors, either by homologous recombination of their encoding genes, or pharmacological blockade with selective antagonists. For this purpose, sleep parameters of knockout mice that do not express these receptors and their wild-type counterparts were monitored during 8 h after injection of citalopram alone or in association with 5-HT(1A) or 5-HT(1B) receptor antagonists. Citalopram induced mainly a dose-dependent inhibition of PS during 2-6 h after injection, which was observed in wild-type and 5-HT(1B)-/- mice, but not in 5-HT(1A)-/- mutants. This PS inhibition was fully antagonized by pretreatment with the 5-HT(1A) antagonist WAY 100635, but only partially with the 5-HT(1B) antagonist GR 127935. These data indicate that the action of the SSRI citalopram on sleep in the mouse is essentially mediated by 5-HT(1A) receptors. Such a mechanism of action provides further support to the clinical strategy of antidepressant augmentation by 5-HT(1A) antagonists, because the latter would also counteract the direct sleep-inhibitory side-effects of SSRIs.
Collapse
Affiliation(s)
- Christelle Monaca
- INSERM U288, NeuroPsychoPharmacologie Moléculaire Cellulaire et Fonctionnelle, CHU Pitié-Salpêtrière-91, Boulevard de l'Hôpital, 75013 Paris, France
| | | | | | | | | |
Collapse
|
13
|
Python A, Steimer T, de Saint Hilaire Z, Mikolajewski R, Nicolaidis S. Extracellular serotonin variations during vigilance states in the preoptic area of rats: a microdialysis study. Brain Res 2001; 910:49-54. [PMID: 11489253 DOI: 10.1016/s0006-8993(01)02477-5] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
Numerous studies have shown that serotonergic transmission decreases from waking (W) to slow wave sleep (SWS) to paradoxical sleep (PS), suggesting an active role of serotonin (5-HT) in W but not in sleep. Conversely, the inhibition of 5-HT activity produces insomnia. This insomnia can be reversed by injections of 5-hydroxytryptophan in the preoptic area (POA), suggesting that 5-HT is necessary in this cerebral structure for sleep. Using microdialysis, we studied, 5-HT variations in the POA of rats in relation to vigilance states. 5-HT levels were higher during W than during during SWS and PS. 5-HT increased just before the rats fell asleep and then decreased during sleep. A decreased 5-HT transmission was also observed from SWS to PS. These data document a positive correlation between 5-HT levels in POA and wakefulness. Moreover, these observations are in favour of a permissive role of 5-HT in the POA during PS. A comparison between the POA and the prefrontal cortex in the sleep-wake cycle is discussed.
Collapse
Affiliation(s)
- A Python
- Sleep Laboratory, HUG, Belle-Idée, 2 Chemin du Petit-Bel-Air, 1225 Chêne-Bourg, Switzerland
| | | | | | | | | |
Collapse
|
14
|
Sørensen E, Bjorvatn B, Ursin R. Sleep-wake effects following the selective 5-HT(1A) receptor antagonist p-MPPI in the freely moving rat. Behav Brain Res 2000; 114:31-8. [PMID: 10996044 DOI: 10.1016/s0166-4328(00)00219-9] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
The 5-HT(1A) receptors appear to play an important role in the serotonergic modulation of sleep and waking. Both presynaptic somatodendritic 5-HT(1A) autoreceptors and postsynaptic 5-HT(1A) heteroreceptors may be involved. The present study addressed the question of whether the selective 5-HT(1A) receptor antagonist 4-(2'-methoxy-phenyl)-1-[2'-(n-2"-pyridinyl)-p-iodobenzamido]-ethy l-p iperazine (p-MPPI) affected sleep and waking and whether such an effect would be dose-related. Polygraphic recording of sleep and waking in freely moving rats was employed following control injection and three doses of p-MPPI (1, 5 and 10 mg/kg i.p. in a balanced order design. Waking was increased and deep slow wave sleep decreased, while rapid eye movement (REM) sleep was suppressed over the first 6 h following injection, compared to after control injection. REM sleep was also suppressed following 10 mg/kg i.p. of p-MPPI as compared to following 1 mg/kg i.p. of p-MPPI. The interpretation of the effects is complex and the effects are not easily compatible with a simple model for serotonergic sleep-waking modulation. However, the REM sleep reduction probably reflects p-MPPIs ability to block the presynaptic 5-HT(1A) autoreceptors, increasing the firing activity in the serotonergic neurones and possibly inhibiting serotonin sensitive REM sleep active neurones.
Collapse
Affiliation(s)
- E Sørensen
- Department of Physiology, University of Bergen, Arstadveien 19, N-5009, Bergen, Norway.
| | | | | |
Collapse
|
15
|
Homeostatic regulation of serotonergic function by the serotonin transporter as revealed by nonviral gene transfer. J Neurosci 2000. [PMID: 10864964 DOI: 10.1523/jneurosci.20-13-05065.2000] [Citation(s) in RCA: 38] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
With the aim of exploring the relationship between the serotonin transporter (5-HTT or SERT) and the activity level of serotonin (5-HT) neurotransmission, in vivo expression of this protein was specifically altered using a nonviral DNA transfer method. Plasmids containing the entire coding sequence or a partial antisense sequence of the 5-HTT gene were complexed with the cationic polymer polyethylenimine and injected into the dorsal raphe nucleus of adult male rats. Significant increase or decrease in both [(3)H]citalopram binding and [(3)H]5-HT synaptosomal uptake were observed in various brain areas up to 2 weeks after a single administration of the sense plasmid or 7 d after injection of the short antisense plasmid, respectively. Such changes in 5-HTT expression were associated with functional alterations in 5-HT neurotransmission, as shown by the increased capacity of 5-HT(1A) receptor stimulation to enhance [(35)S]GTP-gamma-S binding onto the dorsal raphe nucleus in sections from rats injected with the sense plasmid. Conversely, both a decrease in 5-HT(1A)-mediated [(35)S]GTP-gamma-S binding and a reduced potency of the 5-HT(1A) receptor agonist ipsapirone to inhibit neuronal firing were observed in the dorsal raphe nucleus of antisense plasmid-injected rats. Furthermore, changes in brain 5-HT and/or 5-HIAA levels, and sleep wakefulness circadian rhythm in the latter animals demonstrated that altered expression of 5-HTT by recombinant plasmids has important functional consequences on central 5-HT neurotransmission in adult rats.
Collapse
|
16
|
Portas CM, Bjorvatn B, Ursin R. Serotonin and the sleep/wake cycle: special emphasis on microdialysis studies. Prog Neurobiol 2000; 60:13-35. [PMID: 10622375 DOI: 10.1016/s0301-0082(98)00097-5] [Citation(s) in RCA: 199] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Abstract
Several areas in the brainstem and forebrain are important for the modulation and expression of the sleep/wake cycle. Even if the first observations of biochemical events in relation to sleep were made only 40 years ago, it is now well established that several neurotransmitters, neuropeptides, and neurohormones are involved in the modulation of the sleep/wake cycle. Serotonin has been known for many years to play a role in the modulation of sleep, however, it is still very controversial how and where serotonin may operate this modulation. Early studies suggested that serotonin is necessary to obtain and maintain behavioral sleep (permissive role on sleep). However, more recent microdialysis experiments provide evidence that the level of serotonin during W is higher in most cortical and subcortical areas receiving serotonergic projections. In this view the level of extracellular serotonin would be consistent with the pattern of discharge of the DRN serotonergic neurons which show the highest firing rate during W, followed by a decrease in slow wave sleep and by virtual electrical silence during REM sleep. This suggests that during waking serotonin may complement the action of noradrenaline and acetylcholine in promoting cortical responsiveness and participate to the inhibition of REM-sleep effector neurons in the brainstem (inhibitory role on REM sleep). The apparent inconsistency between an inhibitory and a facilitatory role played by serotonin on sleep has at least two possible explanations. On the one hand serotonergic modulation on the sleep/wake cycle takes place through a multitude of post-synaptic receptors which mediate different or even opposite responses; on the other hand the achievement of a behavioral state depends on the complex interaction between the serotonergic and other neurotransmitter systems. The main aim of this commentary is to review the role of brain serotonin in relation to the sleep/wake cycle. In particular we highlight the importance of microdialysis for on-line monitoring of the level of serotonin in different areas of the brain across the sleep/wake cycle.
Collapse
Affiliation(s)
- C M Portas
- Wellcome Department of Cognitive Neurology, Institute of Neurology, UCL, London, UK
| | | | | |
Collapse
|
17
|
Maudhuit C, Jolas T, Chastanet M, Hamon M, Adrien J. Reduced inhibitory potency of serotonin reuptake blockers on central serotoninergic neurons in rats selectively deprived of rapid eye movement sleep. Biol Psychiatry 1996; 40:1000-7. [PMID: 8915559 DOI: 10.1016/0006-3223(95)00583-8] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
Previous studies showed that chronic deprivation of rapid eye movement (REM) sleep had the same behavioral effects as antidepressant drugs in helpless rats. Since long-term treatment with antidepressants is known to affect central serotoninergic neurotransmission, we investigated whether REM sleep deprivation also exerts an influence on the activity of serotoninergic neurons within the dorsal raphe nucleus (DRN) in rats. REM sleep deprivation was performed using the platform technique. Recording of serotoninergic neurons in the DRN revealed no difference in the basal firing rate, but a reduced inhibitory response to the selective serotonin (5-HT) reuptake blockers cericlamine and citalopram after repeated but not acute REM sleep deprivation. These observations suggest that REM sleep deprivation renders serotoninergic DRN neurons less sensitive to the inhibitory effect of 5-HT reuptake blockers, probably because of functional desensitization of somatodendritic 5-HT1A autoreceptors, like that previously reported after chronic treatment with several antidepressants. Accordingly, REM sleep deprivation might alleviate depression through neurophysiological mechanisms similar to those induced by antidepressants.
Collapse
Affiliation(s)
- C Maudhuit
- INSERM U288, CHU Pitié-Salpêtrière, Paris, France
| | | | | | | | | |
Collapse
|
18
|
Bertorelli R, Ferri N, Adami M, Ongini E. Effects of four antiepileptic drugs on sleep and waking in the rat under both light and dark phases. Pharmacol Biochem Behav 1996; 53:559-65. [PMID: 8866955 DOI: 10.1016/0091-3057(95)02050-0] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
Sedation is a common side effect of anticonvulsant drug therapy. To find out whether the new antiepileptic drugs, felbamate and lamotrigine, are able to produce sedation, we carried out electroencephalographic (EEG) studies in the rat to measure drug effects on sleep-wake patterns, during both light and dark phases. For comparison, the reference drugs, carbamazepine and phenobarbital, were also studied. EEG activity was recorded for 6 h after oral (PO) administration of drugs or vehicle, and the stages of wakefulness, rapid eye movements (REM) sleep and non-REM sleep were classified thereafter. In the light phase, felbamate (30-300 mg/kg) did not produce sedative effects, while lamotrigine (3-30 mg/kg) increased wakefulness at each dose tested. Carbamazepine (10-100 mg/kg) did not produce sleep-wake alterations, and phenobarbital (100 mg/kg) markedly suppressed REM. In the dark phase, felbamate (300 mg/kg), lamotrigine (30 mg/kg), and carbamazepine (100 mg/kg) reduced REM but did not change the total amount of sleep. Phenobarbital, at 100 mg/kg, markedly increased total sleep and greatly reduced REM. This study shows that the anticonvulsant drugs examined have different effects on the states of sleep and wakefulness in the rat. The data are discussed on the basis of the mechanism of action that characterizes each individual drug.
Collapse
Affiliation(s)
- R Bertorelli
- Research Laboratories, Schering-Plough, Milan, Italy
| | | | | | | |
Collapse
|